Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3
Open Access
- 28 May 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2198-2204
- https://doi.org/10.1002/ijc.24601
Abstract
Signal transducer and activator of transcription 3 (STAT3) is activated in a variety of human cancers, including ovarian cancer. The molecular mechanism by which the STAT3 is activated in cancer cells is poorly understood. We observed that human ovarian xenograft tumors (A2780) in mice were severely hypoxic (pO2 ∼ 2 mmHg). We further observed that hypoxic exposure significantly increased the phosphorylation of STAT3 (pSTAT3) at the Tyr705 residue in A2780 cell line. The pSTAT3 (Tyr705) level was highly dependent on cellular oxygenation levels, with a significant increase at 2, and without any change in the pSTAT3 (Ser727) or total STAT3 levels. The pSTAT3 (Tyr705) elevation following hypoxic exposure could be reversed within 12 hr after returning the cells to normoxia. The increased level of pSTAT3 was partly mediated by increased levels of reactive oxygen species generation in the hypoxic cancer cells. Conventional chemotherapeutic drugs cisplatin and taxol were far less effective in eliminating the hypoxic ovarian cancer cells suggesting a role for pSTAT3 in cellular resistance to chemotherapy. Inhibition of STAT3 by AG490 followed by treatment with cisplatin or taxol resulted in a significant increase in apoptosis suggesting that hypoxia‐induced STAT3 activation is responsible for chemoresistance. The results have important clinical implications for the treatment of hypoxic ovarian tumors using STAT3‐specific inhibitors. © 2009 UICCKeywords
Funding Information
- NIH (CA-102264)
- Kaleidoscope of Hope Foundation, NJ
This publication has 46 references indexed in Scilit:
- Repeated tumor pO2 measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapyRadiotherapy and Oncology, 2009
- NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiolsJournal of Translational Medicine, 2008
- NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and mdulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenograftsCell Cycle, 2008
- ERK-Dependent MKP-1–Mediated Cisplatin Resistance in Human Ovarian Cancer CellsCancer Research, 2007
- Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cellsBiochemical and Biophysical Research Communications, 2007
- In vivo imaging of changes in tumor oxygenation during growth and after treatmentMagnetic Resonance in Medicine, 2007
- The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosisCancer, 2006
- Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of FlavonoidsCancer Research, 2006
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Stat proteins and oncogenesisJournal of Clinical Investigation, 2002